Mineralocorticoid Receptor Antagonists

"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.

Descriptor ID	D000451
MeSH Number(s)	D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
Concept/Terms	Mineralocorticoid Receptor Antagonists Mineralocorticoid Receptor Antagonists Antagonists, Mineralocorticoid Receptor Receptor Antagonists, Mineralocorticoid Mineralocorticoid Antagonists Antagonists, Mineralocorticoid Aldosterone Receptor Antagonists Antagonists, Aldosterone Receptor Receptor Antagonists, Aldosterone Aldosterone Antagonists Aldosterone Antagonists Antagonists, Aldosterone

Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Mineralocorticoid Receptor Antagonists [D06.347.700]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Mineralocorticoid Receptor Antagonists [D27.505.696.399.450.600]
Natriuretic Agents [D27.505.696.560]
Diuretics [D27.505.696.560.500]
Diuretics, Potassium Sparing [D27.505.696.560.500.726]
Mineralocorticoid Receptor Antagonists [D27.505.696.560.500.726.249]

Below are MeSH descriptors whose meaning is related to "Mineralocorticoid Receptor Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 10 publications over 8 distinct years, with a maximum of 2 publications in 2021 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	0	1	1
2013	1	0	1
2015	0	1	1
2016	0	1	1
2018	1	0	1
2021	2	0	2
2022	0	1	1
2024	1	1	2

Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.

Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, Kiernan MS, Kapur NK, Testani JM. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. J Card Fail. 2024 Nov; 30(11):1522-1526.

View in: PubMed
Schwann AN, Jaffe LM, Givertz MM, Wood KL, Engelman DT. Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery. Ann Thorac Surg. 2024 10; 118(4):792-800.

View in: PubMed
Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022 10 11; 43(38):3781-3791.

View in: PubMed
Brinkley DM, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021 12; 40(12):1605-1613.

View in: PubMed
Verma A, Patel AB. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. Trends Endocrinol Metab. 2021 05; 32(5):261-263.

View in: PubMed
Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 07; 131(7):837-841.

View in: PubMed
Khazanie P, Hammill BG, Patel CB, Kiernan MS, Cooper LB, Arnold SV, Fendler TJ, Spertus JA, Curtis LH, Hernandez AF. Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. J Card Fail. 2016 Sep; 22(9):672-9.

View in: PubMed
Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, Robertson D, Shibao CA, Biaggioni I. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. Hypertension. 2016 Feb; 67(2):424-9.

View in: PubMed
Hassan M, Qureshi W, Sroujieh LS, Albashaireh D, BouMalham S, Liroff M, Amjad W, Khalid F, Hadid H, Alirhayim Z. Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014 Sep; 15(3):278-85.

View in: PubMed
Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, Fairclough DL, Rumsfeld JS, Masoudi FA, Magid DJ. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ Heart Fail. 2014 Jan; 7(1):43-50.

View in: PubMed

People

Explore

Similar Concepts

Top Journals